June 1, 2017
BLA approval for Novo Nordisk’s Rebinyn for heamophilia B
Rebinyn got US FDA’s approval and is hoped to become an important tool for physicians to help patients manage their bleeds.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
May 31, 2017
Mylan may have overcharged U.S. for EpiPen by $1.27 billion: HHS
The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.
May 31, 2017
Asia to be drug delivery technology market fastest-growing region
Drug delivery technology market grows from $1,179.20 billion to $1,669.40 billion at a CAGR of 7.2% from 2016-2021. Oral drug delivery segment is expected to account for the largest share while hospitals segment is expected to account for the largest share of the market and Asia is expected to be fastest-growing region.
May 31, 2017
Novartis warns of U.S. price pressure on Sandoz generics
Novartis warned on Wednesday that price pressure on its generics drugs in the United States has intensified in the second quarter, cutting into its Sandoz division’s sales growth in the world’s largest healthcare market.
May 31, 2017
FDA approves attention-deficit/hyperactivity disorder drug
Apotex, Teva Pharmaceuticals USA, Aurobindo Pharma and Glenmark Pharmaceuticals have won FDA’s approval to market atomoxetine in multiple strengths to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
May 30, 2017
Inventiva welcomes new Board memeber
Inventiva, a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, has appointed Dr Nanna Lüneborg as its Board member, succeeding Mr Philippe Goupit.
May 29, 2017
Deadly brain infection in German MS patient prompts Roche investigation
A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday.
May 29, 2017
Bone Therapeutics welcomes new members of the Board
Bone Therapeutics has appointed Steve Swinson and Damian Marron to its Board of Directors as Non-Executive Directors.
May 29, 2017
FDA OK’s expanded use of Novartis’s cancer drug
The US Food and Drug Administration (FDA) approved the expanded use of Novartis’s Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.